华蟾素联合伊班膦酸钠治疗多发性骨髓瘤骨痛的临床疗效

Clinical efficacy of Huachansu combined with ibandronate sodium in the treatment of multiple myeloma ostealgia

目的探讨华蟾素联合伊班膦酸钠治疗多发性骨髓瘤骨痛的临床疗效。方法选取2018年1月至2021年4月本院收治的60例多发性骨髓瘤患者作为研究对象,按随机数字表法分为观察组和对照组,每组30例。对照组应用伊班膦酸钠,观察组应用华蟾素联合伊班膦酸钠。比较两组疼痛症状、生命质量、不良反应发生情况、治疗依从性。结果治疗后,观察组疼痛评分低于对照组,健康调查量表36(SF-36)评分高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。观察组治疗依从性为96.67%,高于对照组的73.33%,差异有统计学意义(P<0.05)。结论采取华蟾素联合伊班膦酸钠治疗多发性骨髓瘤患者的临床治疗显著,能有效缓解患者的骨痛症状,安全性高,值得临床推广应用。

Objective To investigate the clinical efficacy of Huachansu combined with ibandronate sodium in the treatment of multiple myeloma ostealgia.Methods 60 patients with multiple myeloma admitted to our hospital from January 2018 to April 2021 were selected as the research subjects,and they were divided into observation group and control group according to random number table method,with 30 cases in each group.The control group was treated with ibandronate sodium,and the observation group was treated with Huachansu combined with ibandronate sodium.The pain symptoms,quality of life,adverse reactions and treatment compliance were compared between the two groups.Results After treatment,the pain score of the observation group was lower than that of the control group,and the short form 36(SF-36)score was higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.The treatment compliance in the observation group was 96.67%,which was higher than 73.33% in the control group,and the difference was statistically significant(P<0.05).Conclusion Huachansu combined with ibandronate sodium in the treatment of patients with multiple myeloma has significant clinical treatment,which can effectively relieve the bone pain symptoms of patients with high safety,and is worthy of clinical promotion and application.